Table 1.
Demographics and cancer related characteristics of all included patients—surgical and nonsurgical (n=3973)a
| Uterus (n=1811) | Ovary (n=1459) | Cervix (n=462) | Vulva/vagina (n=235) | Total (n=3973) | |
|---|---|---|---|---|---|
| Age (y) | |||||
| 17–19 | 1 (0.1) | 12 (0.8) | 0 (0) | 0 (0) | 13 (0.3) |
| 20–29 | 7 (0.4) | 65 (4.5) | 24 (5.2) | 4 (1.7) | 100 (2.5) |
| 30–39 | 56 (3.1) | 113 (7.8) | 122 (26.4) | 7 (3.0) | 299 (7.5) |
| 40–49 | 175 (9.7) | 265 (18.2) | 144 (31.2) | 22 (9.4) | 608 (15.3) |
| 50–59 | 473 (26.1) | 380 (26.1) | 99 (21.4) | 52 (22.1) | 1004 (25.3) |
| 60–69 | 554 (30.6) | 380 (26.1) | 42 (9.1) | 49 (20.9) | 1027 (25.9) |
| 70–79 | 421 (23.3) | 198 (13.6) | 27 (5.8) | 58 (24.7) | 705 (17.7) |
| 80–89 | 119 (6.6) | 46 (3.2) | 4 (0.9) | 41 (17.5) | 210 (5.3) |
| >90 | 5 (0.3) | 0 (0) | 0 (0) | 2 (0.9) | 7 (0.2) |
| Region | |||||
| Europe & Central Asia | 1122 (62.0) | 820 (56.2) | 272 (58.9) | 188 (80.0) | 2408 (60.6) |
| Latin America & Caribbean | 201 (11.1) | 180 (12.3) | 85 (18.4) | 18 (7.7) | 484 (12.2) |
| East Asia & Pacific | 178 (9.8) | 141 (9.7) | 53 (11.5) | 4 (1.7) | 376 (9.5) |
| South Asia | 74 (4.1) | 177 (12.1) | 18 (3.9) | 8 (3.4) | 277 (7.0) |
| North America | 147 (8.1) | 67 (4.6) | 20 (4.3) | 10 (4.3) | 244 (6.1) |
| Middle East & North Africa | 81 (4.5) | 70 (4.8) | 4 (0.9) | 5 (2.1) | 160 (4.0) |
| Sub-Saharan Africa | 8 (0.4) | 4 (0.27) | 10 (2.2) | 2 (0.9) | 24 (0.6) |
| Income group | |||||
| High | 1400 (77.3) | 982 (67.3) | 321 (69.5) | 197 (83.8) | 2906 (73.1) |
| Upper middle | 305 (16.8) | 222 (15.2) | 115 (24.9) | 30 (12.8) | 705 (17.7) |
| Low-middle | 106 (5.9) | 255 (17.5) | 26 (5.6) | 8 (3.4) | 362 (9.1) |
| BMI (kg/m2) | |||||
| <18.5 | 25 (1.4) | 61 (4.2) | 19 (4.1) | 8 (3.4) | 113 (2.8) |
| 18.5–24.9 | 496 (27.4) | 683 (46.8) | 228 (49.4) | 86 (36.6) | 1495 (37.6) |
| 25–29.9 | 531 (29.3) | 423 (29.0) | 125 (27.1) | 73 (31.1) | 1155 (29.1) |
| 30–34.9 | 363 (20.0) | 184 (12.6) | 57 (12.3) | 37 (15.7) | 642 (16.2) |
| 35–39.9 | 195 (10.8) | 63 (4.3) | 20 (4.3) | 18 (7.7) | 296 (7.5) |
| ≥40 | 184 (10.2) | 37 (2.5) | 9 (2.0) | 9 (3.8) | 239 (6.0) |
| Not available | 17 (0.9) | 8 (0.6) | 4 (0.9) | 4 (1.7) | 33 (0.8) |
| WHO performance status | |||||
| 0 | 1065 (58.8) | 863 (59.2) | 387 (83.8) | 132 (56.2) | 2448 (61.6) |
| 1 | 520 (28.7) | 446 (30.6) | 58 (12.6) | 71 (30.2) | 1095 (27.6) |
| 2 | 124 (6.9) | 102 (7.0) | 5 (1.1) | 19 (8.1) | 250 (6.3) |
| 3 | 20 (1.1) | 13 (0.9) | 0 (0) | 4 (1.7) | 37 (0.9) |
| 4 | 1 (0.1) | 2 (0.1) | 0 (0) | 3 (1.3) | 6 (0.2) |
| Not available | 81 (4.5) | 33 (2.3) | 12 (2.6) | 6 (2.6) | 137 (3.5) |
| CCI | |||||
| 0 | 205 (11.3) | 427 (29.3) | 274 (59.3) | 27 (11.5) | 936 (23.6) |
| 1 | 387 (21.4) | 356 (24.4) | 86 (18.6) | 42 (17.9) | 871 (21.9) |
| 2 | 487 (26.9) | 341 (23.4) | 41 (8.9) | 44 (18.7) | 914 (23.0) |
| 3 | 410 (22.6) | 212 (14.5) | 37 (8.0) | 48 (20.4) | 707 (17.8) |
| 4 | 207 (11.4) | 77 (5.3) | 14 (3.0) | 39 (16.6) | 338 (8.5) |
| 5 | 76 (4.2) | 31 (2.1) | 1 (0.2) | 21 (8.9) | 130 (3.3) |
| 6 | 30 (1.7) | 11 (0.8) | 6 (1.3) | 6 (2.6) | 53 (1.3) |
| 7 | 5 (0.3) | 2 (0.1) | 1 (0.2) | 6 (2.6) | 14 (0.4) |
| 8 | 3 (0.2) | 1 (0.1) | 1 (0.2) | 2 (0.9) | 7 (0.2) |
| 9 | 1 (0.1) | 1 (0.1) | 1 (0.2) | 0 (0) | 3 (0.1) |
| ASA grade | |||||
| 1 | 381 (21.0) | 417 (28.6) | 216 (46.8) | 34 (14.5) | 1048 (26.4) |
| 2 | 1013 (55.9) | 786 (53.9) | 205 (44.4) | 137 (58.3) | 2145 (54.0) |
| 3 | 402 (22.2) | 240 (16.5) | 39 (8.4) | 61 (26.0) | 743 (18.7) |
| 4 | 9 (0.5) | 15 (1.0) | 1 (0.2) | 2 (0.9) | 27 (0.7) |
| 5 | 1 (0.1) | 0 (0) | 1 (0.2) | 0 (0) | 2 (0.1) |
| Not available | 5 (0.3) | 0 (0) | 0 (0) | 0 (0) | 8 (0.2) |
| FIGO stage | |||||
| Not cancer | 58 (3.2) | 81 (5.6) | 57 (12.3) | 24 (10.2) | 221 (5.6) |
| 1 | 1276 (70.5) | 452 (31.0) | 300 (64.9) | 142 (60.4) | 2173 (54.7) |
| 2 | 175 (9.7) | 124 (8.5) | 51 (11.0) | 22 (9.4) | 373 (9.4) |
| 3 | 202 (11.2) | 555 (38.0) | 45 (9.7) | 37 (15.7) | 839 (21.1) |
| 4 | 62 (3.4) | 227 (15.6) | 9 (2.0) | 4 (1.7) | 302 (7.6) |
| Not available | 38 (2.1) | 20 (1.4) | 0 (0) | 6 (2.6) | 65 (1.6) |
| Histology | |||||
| SCC | 22 (1.2) | 31 (2.1) | 323 (69.9) | 198 (84.3) | 578 (14.6) |
| Adenocarcinoma | 1611 (89.0) | 1116 (76.5) | 118 (25.5) | 9 (3.8) | 2854 (71.8) |
| GCST | 13 (0.7) | 110 (7.5) | 0 (0) | 3 (1.3) | 127 (3.2) |
| Other | 139 (7.7) | 34 (2.3) | 7 (1.5) | 18 (7.7) | 198 (5.0) |
| Benign/preinvasive/borderline | 21 (1.2) | 133 (9.1) | 14 (3.0) | 5 (2.1) | 173 (4.4) |
| Not available | 5 (0.3) | 35 (2.4) | 0 (0) | 2 (0.9) | 43 (1.1) |
Data are presented as total number (percentage). Details of operated vs non-operated group separately, are presented in Supplemental Table 2 and 4.
ASA grade, American Society of Anaesthesiologists Physical Status Classification system; BMI, body mass index; CCI, Charlson Comorbidity Index; FIGO, International Federation of Gynaecology and Obstetrics; GCST, germ cell, sex cord stromal or trophoblastic tumors; NACT, neoadjuvant chemotherapy; SCC, squamous cell carcinoma; WHO, World Health Organization.
Fotopoulou. Gynecologic cancer surgery during the COVID-19 pandemic. Am J Obstet Gynecol 2022.
a
Six patients (0.1%) did not have a recorded cancer site.